Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.80 EUR
428.98 M EUR
980.78 M EUR
115.68 M
About Halozyme Therapeutics, Inc.
Sector
Industry
CEO
Helen I. Torley
Website
Headquarters
San Diego
Founded
1998
ISIN
US40637H1095
FIGI
BBG01TNY07L6
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028Yield to maturity
—
Maturity date
Aug 15, 2028
HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027Yield to maturity
—
Maturity date
Mar 1, 2027
See all 1HALO bonds
Curated watchlists where 1HALO is featured.
Frequently Asked Questions
The current price of 1HALO is 66.48 EUR — it has increased by 1.65% in the past 24 hours. Watch Halozyme Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Halozyme Therapeutics, Inc. stocks are traded under the ticker 1HALO.
1HALO stock has risen by 2.31% compared to the previous week, the month change is a 9.99% rise, over the last year Halozyme Therapeutics, Inc. has showed a 29.04% increase.
We've gathered analysts' opinions on Halozyme Therapeutics, Inc. future price: according to them, 1HALO price has a max estimate of 77.47 EUR and a min estimate of 43.42 EUR. Watch 1HALO chart and read a more detailed Halozyme Therapeutics, Inc. stock forecast: see what analysts think of Halozyme Therapeutics, Inc. and suggest that you do with its stocks.
1HALO reached its all-time high on Sep 12, 2025 with the price of 65.54 EUR, and its all-time low was 43.06 EUR and was reached on May 14, 2025. View more price dynamics on 1HALO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1HALO stock is 1.62% volatile and has beta coefficient of 0.11. Track Halozyme Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Halozyme Therapeutics, Inc. there?
Today Halozyme Therapeutics, Inc. has the market capitalization of 7.76 B, it has decreased by −2.90% over the last week.
Yes, you can track Halozyme Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Halozyme Therapeutics, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
1HALO earnings for the last quarter are 1.31 EUR per share, whereas the estimation was 1.06 EUR resulting in a 23.77% surprise. The estimated earnings for the next quarter are 1.37 EUR per share. See more details about Halozyme Therapeutics, Inc. earnings.
Halozyme Therapeutics, Inc. revenue for the last quarter amounts to 276.50 M EUR, despite the estimated figure of 242.71 M EUR. In the next quarter, revenue is expected to reach 287.48 M EUR.
1HALO net income for the last quarter is 140.20 M EUR, while the quarter before that showed 109.16 M EUR of net income which accounts for 28.44% change. Track more Halozyme Therapeutics, Inc. financial stats to get the full picture.
No, 1HALO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 23, 2025, the company has 350 employees. See our rating of the largest employees — is Halozyme Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Halozyme Therapeutics, Inc. EBITDA is 648.87 M EUR, and current EBITDA margin is 62.32%. See more stats in Halozyme Therapeutics, Inc. financial statements.
Like other stocks, 1HALO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Halozyme Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.